Skip to Content
Merck
  • RhoA drives actin compaction to restrict axon regeneration and astrocyte reactivity after CNS injury.

RhoA drives actin compaction to restrict axon regeneration and astrocyte reactivity after CNS injury.

Neuron (2021-09-12)
Sina Stern, Brett J Hilton, Emily R Burnside, Sebastian Dupraz, Emily E Handley, Jessica M Gonyer, Cord Brakebusch, Frank Bradke
ABSTRACT

An inhibitory extracellular milieu and neuron-intrinsic processes prevent axons from regenerating in the adult central nervous system (CNS). Here we show how the two aspects are interwoven. Genetic loss-of-function experiments determine that the small GTPase RhoA relays extracellular inhibitory signals to the cytoskeleton by adapting mechanisms set in place during neuronal polarization. In response to extracellular inhibitors, neuronal RhoA restricts axon regeneration by activating myosin II to compact actin and, thereby, restrain microtubule protrusion. However, astrocytic RhoA restricts injury-induced astrogliosis through myosin II independent of microtubules by activating Yes-activated protein (YAP) signaling. Cell-type-specific deletion in spinal-cord-injured mice shows that neuronal RhoA activation prevents axon regeneration, whereas astrocytic RhoA is beneficial for regenerating axons. These data demonstrate how extracellular inhibitors regulate axon regeneration, shed light on the capacity of reactive astrocytes to be growth inhibitory after CNS injury, and reveal cell-specific RhoA targeting as a promising therapeutic avenue.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Verteporfin, ≥94% (HPLC)
Sigma-Aldrich
(−)-Blebbistatin, solid, synthetic
Sigma-Aldrich
Phalloidin–Atto 647N, BioReagent, suitable for fluorescence, ≥80% (HPLC)
Roche
cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail, Protease Inhibitor Cocktail Tablets provided in a glass vial, Tablets provided in a glass vial
Sigma-Aldrich
CA3, ≥97% (HPLC)
Roche
Laminin, from mouse Engelbreth-Holm-Swarm (EHS) sarcoma